A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs GSK 3390107A (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Jul 2015 New trial record